Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Tzu Tai

Showing results (41-50 of 211) with videos related to

Pageof 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2017
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple MyelomaMorihiko Sagawa, Hiroto Ohguchi, Takeshi Harada, et al.
Experimental Hematology|March 8, 2002
Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implicationsYu-Tzu Tai, Klaus Podar, Stine-Kathrein Kraeft, et al.
British Journal of Haematology|May 20, 2003
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cellsToshiaki Hayashi, Steven P Treon, Teru Hideshima, et al.
Blood|July 16, 2016
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implicationGang An, Chirag Acharya, Xiaoyan Feng, et al.
Experimental Hematology|June 26, 2007
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma modelLaurence Catley, Teru Hideshima, Dharminder Chauhan, et al.
Blood|August 27, 2020
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implicationsDaisuke Ogiya, Jiye Liu, Hiroto Ohguchi, et al.
Blood|February 25, 2016
MUC1-C drives MYC in multiple myelomaAshujit Tagde, Hasan Rajabi, Audrey Bouillez, et al.
Blood|September 18, 2012
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cellsZe Tian, Jian-jun Zhao, Yu-Tzu Tai, et al.
Cancer Research|October 20, 2004
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomibKlaus Podar, Reshma Shringarpure, Yu-Tzu Tai, et al.
Nature Communications|May 2, 2018
Widespread intronic polyadenylation diversifies immune cell transcriptomesIrtisha Singh, Shih-Han Lee, Adam S Sperling, et al.
Pageof 22

Showing results (41-50 of 211) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2017
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple MyelomaMorihiko Sagawa, Hiroto Ohguchi, Takeshi Harada, et al.
Experimental Hematology|March 8, 2002
Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implicationsYu-Tzu Tai, Klaus Podar, Stine-Kathrein Kraeft, et al.
British Journal of Haematology|May 20, 2003
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cellsToshiaki Hayashi, Steven P Treon, Teru Hideshima, et al.
Blood|July 16, 2016
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implicationGang An, Chirag Acharya, Xiaoyan Feng, et al.
Experimental Hematology|June 26, 2007
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma modelLaurence Catley, Teru Hideshima, Dharminder Chauhan, et al.
Blood|August 27, 2020
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implicationsDaisuke Ogiya, Jiye Liu, Hiroto Ohguchi, et al.
Blood|February 25, 2016
MUC1-C drives MYC in multiple myelomaAshujit Tagde, Hasan Rajabi, Audrey Bouillez, et al.
Blood|September 18, 2012
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cellsZe Tian, Jian-jun Zhao, Yu-Tzu Tai, et al.
Cancer Research|October 20, 2004
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomibKlaus Podar, Reshma Shringarpure, Yu-Tzu Tai, et al.
Nature Communications|May 2, 2018
Widespread intronic polyadenylation diversifies immune cell transcriptomesIrtisha Singh, Shih-Han Lee, Adam S Sperling, et al.
Pageof 22